Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives ...

Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application

Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug application, raising ...
The Pharma Letter

FDA setback for Aquestive Thera’s Anaphylm

New Jersey, USA-based Aquestive Therapeutics saw its shares plummet nearly 48% to $3.25 (Nasdaq: AQST) pre-market today, ...

Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces Regulatory Development for Anaphylm (dibutepinephrine) Sublingual Film and Provides Business Update

Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency's review of Anaphylm NDA ...